Article authored and contributed to PharmaLeaders by: Carlo Chatman, Power PR Cell and gene therapies are dominating the world of drug development. With the promise of significant breakthroughs in treatment […]
Featured Article
The Importance of Pharma Marketers Engaging with the Nation’s Leading Prescribers
By Andrea
Contributed to PharmaLeaders by: Richard Zwickel, Chairman and CEO POCN Group Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 cases […]
White Papers
Automation of Process Control within the Pharmaceutical Industry
While most pharmaceutical businesses have adopted process automation in one format or another, the technology has evolved considerably over the past … FREE Download

Pediatric Gene Therapy
The European approvals of Glybera® in 2012 and Strimvelis® in 2016 seem likely to be the vanguard of the therapeutic revolution heralded by the … FREE Download
Industry News
Daiichi Sankyo receives approval for ENHERTU in Japan
Daiichi Sankyo has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ENHERTU (trastuzumab deruxtecan), a treatment for adult patients with HER2 low (IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy. ENHERTU, … [Read More...]
Iovance Biotherapeutics submits BLA to FDA for advanced melanoma drug lifileucel
Iovance Biotherapeutics has completed submission of the Biologics License Application (BLA) for lifileucel to the US Food and Drug Administration (FDA). A tumour infiltrating lymphocyte (TIL) therapy, lifileucel is designed to treat patients with advanced (unresectable … [Read More...]
Macomics signs collaboration deal with Ono Pharmaceutical
Macomics and Ono Pharmaceutical have entered into a global collaboration deal for the discovery and development of macrophage-targeting antibody therapy for cancer. Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates … [Read More...]
Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications
Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications. Dewpoint’s discovery platform related to biomolecular condensates will be used to identify the drug … [Read More...]